Wuxi Biologics Unspadr2 Stock Current Valuation
| 1FW1 Stock | EUR 4.18 0.08 1.95% |
Valuation analysis of WUXI BIOLOGICS UNSPADR2 helps investors to measure WUXI BIOLOGICS's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that WUXI BIOLOGICS's price fluctuation is very risky at this time. Calculation of the real value of WUXI BIOLOGICS UNSPADR2 is based on 3 months time horizon. Increasing WUXI BIOLOGICS's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the WUXI stock is determined by what a typical buyer is willing to pay for full or partial control of WUXI BIOLOGICS UNSPADR2. Since WUXI BIOLOGICS is currently traded on the exchange, buyers and sellers on that exchange determine the market value of WUXI Stock. However, WUXI BIOLOGICS's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.18 | Real 3.55 | Hype 4.18 | Naive 4.12 |
The real value of WUXI Stock, also known as its intrinsic value, is the underlying worth of WUXI BIOLOGICS UNSPADR2 Company, which is reflected in its stock price. It is based on WUXI BIOLOGICS's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of WUXI BIOLOGICS's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of WUXI BIOLOGICS UNSPADR2 helps investors to forecast how WUXI stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of WUXI BIOLOGICS more accurately as focusing exclusively on WUXI BIOLOGICS's fundamentals will not take into account other important factors: WUXI BIOLOGICS UNSPADR2 Company Current Valuation Analysis
WUXI BIOLOGICS's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, WUXI BIOLOGICS UNSPADR2 has a Current Valuation of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current valuation for all Germany stocks is 100.0% higher than that of the company.
WUXI Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses WUXI BIOLOGICS's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of WUXI BIOLOGICS could also be used in its relative valuation, which is a method of valuing WUXI BIOLOGICS by comparing valuation metrics of similar companies.WUXI BIOLOGICS is currently under evaluation in current valuation category among its peers.
WUXI Fundamentals
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0551 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.31 % | |||
| Shares Outstanding | 2.11 B | |||
| Shares Owned By Institutions | 0.01 % | |||
| Price To Earning | 238.12 X | |||
| Revenue | 13.09 B | |||
| Gross Profit | 4.83 B | |||
| EBITDA | 4.6 B | |||
| Net Income | 1.69 B | |||
| Cash And Equivalents | 8.48 B | |||
| Cash Per Share | 4.15 X | |||
| Total Debt | 3.33 B | |||
| Debt To Equity | 0.16 % | |||
| Current Ratio | 3.16 X | |||
| Book Value Per Share | 16.51 X | |||
| Cash Flow From Operations | 1.88 B | |||
| Earnings Per Share | 0.25 X | |||
| Number Of Employees | 10.59 K | |||
| Beta | 1.11 | |||
| Market Capitalization | 32.39 B | |||
| Z Score | 5.4 |
About WUXI BIOLOGICS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze WUXI BIOLOGICS UNSPADR2's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of WUXI BIOLOGICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of WUXI BIOLOGICS UNSPADR2 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in WUXI Stock
WUXI BIOLOGICS financial ratios help investors to determine whether WUXI Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in WUXI with respect to the benefits of owning WUXI BIOLOGICS security.